About Faron Pharmaceuticals Oy (LON:FARN)
Faron Pharmaceuticals Oy is a Finland-based biopharmaceutical company engaged in the biotechnology and medical research industry. The Company develops late stage clinical drugs focusing on acute organ traumas, cancer immunotherapy and vascular damage. Its product pipeline includes Traumakine (FP-1201-lyo), an Acute Respiratory Distress Syndrome (ARDS) treatment that is in phase Three development; and Clevegen (FP-1304), an anti-Clever-1 immunotheraphy tumor targeting candidate that is in pre-clinical stage development.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Bio Therapeutic Drugs
- Symbol: LON:FARN
- CUSIP: N/A
- Web: www.faron.com
- Trailing EPS: GBX (0.44)
- Net Margins: -103,042.90%
- Return on Equity: -141.29%
- Return on Assets: -86.22%
- Outstanding Shares: 29,160,000
Frequently Asked Questions for Faron Pharmaceuticals Oy (LON:FARN)
What is Faron Pharmaceuticals Oy's stock symbol?
Faron Pharmaceuticals Oy trades on the London Stock Exchange (LON) under the ticker symbol "FARN."
Where is Faron Pharmaceuticals Oy's stock going? Where will Faron Pharmaceuticals Oy's stock price be in 2017?
1 brokerages have issued 1-year target prices for Faron Pharmaceuticals Oy's shares. Their predictions range from GBX 723 to GBX 723. On average, they anticipate Faron Pharmaceuticals Oy's share price to reach GBX 723 in the next year. View Analyst Ratings for Faron Pharmaceuticals Oy.
Who are some of Faron Pharmaceuticals Oy's key competitors?
Some companies that are related to Faron Pharmaceuticals Oy include uniQure N.V. (QURE), Kura Oncology (KURA), Jounce Therapeutics (JNCE), Atara Biotherapeutics (ATRA), BioCryst Pharmaceuticals (BCRX), Aurinia Pharmaceuticals (AUPH), GlycoMimetics (GLYC), Insys Therapeutics (INSY), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals Holdings (CRBP), Seres Therapeutics (MCRB), CymaBay Therapeutics (CBAY), MannKind Corporation (MNKD), Calithera Biosciences (CALA), NuCana PLC Sponsored ADR (NCNA), Mersana Therapeutics (MRSN), AVEO Pharmaceuticals (AVEO) and Mast Therapeutics (SVRA).
Who are Faron Pharmaceuticals Oy's key executives?
Faron Pharmaceuticals Oy's management team includes the folowing people:
- Markku Jalkanen, Chief Executive Officer, Founder, Member of the Executive Board
- Yrjo Erik Kristian Wichmann, Chief Financial Officer, Member of the Executive Board
- Mikael Maksimow, Vice President Operations
- Ilse Piippo, Vice President Drug Development, Chief Medical Officer
- Matti Karvonen, Medical Director
- Frank Murdoch Armstrong, Non-Executive Chairman of the Board (Age 60)
- Matti Manner, Non-Executive Vice Chairman of the Board (Age 64)
- Juho Jalkanen, Non-Executive Director
- Jonathan Knowles, Non-Executive Director (Age 70)
- Huaizheng Peng, Non-Executive Director (Age 54)
How do I buy Faron Pharmaceuticals Oy stock?
Shares of Faron Pharmaceuticals Oy and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Faron Pharmaceuticals Oy's stock price today?
One share of Faron Pharmaceuticals Oy stock can currently be purchased for approximately GBX 830.
How big of a company is Faron Pharmaceuticals Oy?
Faron Pharmaceuticals Oy has a market capitalization of £238.35 million.
How can I contact Faron Pharmaceuticals Oy?
MarketBeat Community Rating for Faron Pharmaceuticals Oy (LON FARN)MarketBeat's community ratings are surveys of what our community members think about Faron Pharmaceuticals Oy and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Faron Pharmaceuticals Oy's mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The company can be reached via phone at +358-2-4695151.
Analysts' Consensus Ratings for Faron Pharmaceuticals Oy (LON:FARN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 723|Consensus Price Target History for Faron Pharmaceuticals Oy (LON:FARN)
Analysts' Ratings History for Faron Pharmaceuticals Oy (LON:FARN)
(Data available from 11/17/2015 forward)
|10/2/2017||Panmure Gordon||Reiterated Rating||Buy|
|1/4/2016||RX Securities||Initiated Coverage||Buy||GBX 375|
Earnings History for Faron Pharmaceuticals Oy (LON:FARN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Faron Pharmaceuticals Oy (LON:FARN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Faron Pharmaceuticals Oy (LON:FARN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Faron Pharmaceuticals Oy (LON FARN)Insider Trades by Quarter for Faron Pharmaceuticals Oy (LON FARN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/11/2017||Frank Armstrong||Insider||Buy||1,250||GBX 800||£10,000|
|9/8/2017||Jonathan Knowles||Insider||Buy||63,000||GBX 725||£456,750|
|4/25/2017||Jonathan Knowles||Insider||Buy||1,000||GBX 635||£6,350|
|3/31/2017||Jonathan Knowles||Insider||Buy||19,000||GBX 550||£104,500|
|12/13/2016||Jonathan Knowles||Insider||Buy||7,000||GBX 275||£19,250|
|12/12/2016||Jonathan Knowles||Insider||Buy||10,000||GBX 265||£26,500|
|9/23/2016||Leopoldo Zambeletti||Insider||Buy||4,000||GBX 250||£10,000|
Headline Trends for Faron Pharmaceuticals Oy (LON:FARN)
Latest Headlines for Faron Pharmaceuticals Oy (LON FARN)
Financials are not available for this stock.
Faron Pharmaceuticals Oy (LON FARN) Chart for Friday, November, 17, 2017